

Appl. No. : **10/026,066**
Filed : **December 7, 2001**

AMENDMENTS TO THE CLAIMS

1. (Previously presented) A composition suitable for adoptive administration to a human, comprising a first isolated T cell in a pharmaceutically acceptable formulation suitable for adoptive administration to a human, the formulation comprising a pharmaceutically acceptable carrier, adjuvant, diluent, or excipient, wherein said T cell expresses a T cell receptor specific for an MHC-peptide complex comprising a first housekeeping epitope, wherein the housekeeping epitope is derived from a first antigen associated with a first target cell.

2. (Previously presented) The composition of Claim 1, comprising a T cell clone comprising said isolated T cell.

3. (Previously presented) The composition of Claim 1, comprising a polyclonal population of T cells comprising said isolated T cell.

4. (Previously presented) The composition of Claim 1, wherein said T cell is produced by an in vitro immunization.

5. (Previously presented) The composition of Claim 1, wherein said T cell is isolated from an immunized animal.

6-28 (Cancelled)

29. (Previously presented) The composition of Claim 1, wherein the first target cell is a neoplastic cell.

30. (Previously presented) The composition of Claim 1, wherein the first antigen is a tumor associated antigen.

31. (Previously presented) The composition of Claim 30, wherein the tumor associated antigen is a cancer-testis antigen.

32. (Previously presented) The composition of Claim 30, wherein the tumor associated antigen is selected from the group consisting of NY-ESO, PSMA, SSX-2 and PRAME.

33. (Previously presented) The composition of Claim 30, wherein the tumor associated antigen is a melanoma differentiation antigen.

34. (Previously presented) The composition of Claim 33, wherein the melanoma differentiation antigen is selected from the group consisting of tyrosinase, MelanA, and gp100.

35. (Previously presented) The composition of Claim 1, wherein the MHC is A2.

Appl. No. : **10/026,066**
Filed : **December 7, 2001**

36. (Previously presented) The composition of Claim 1, wherein the MHC is selected from the group consisting of A1, A3, A24, B7 and B8.

37. (Cancelled)

38. (Previously presented) The composition of Claim 37, wherein said first antigen and said second antigen are the same.

39. (Previously presented) The composition of Claim 37, wherein said first target cell and said second target cell are the same.

40. (Previously presented) The composition of Claim 1, comprising from about 10^5 to about 10^8 T cells.

41. (Previously presented) The composition of Claim 1, comprising from about 10^8 to about 10^{11} T cells.

42. (Previously presented) A composition suitable for adoptive administration to an animal, comprising at least a first and a second isolated T cell population, wherein said first population expresses a T cell receptor specific for a first MHC-peptide complex comprising a first housekeeping epitope derived from a first antigen associated with a first target cell, and wherein said second population expresses a T cell receptor specific for a second MHC-peptide complex comprising a second housekeeping epitope derived from a second antigen associated with a second target cell, wherein the first housekeeping epitope and the second housekeeping epitope are not the same.

43. (Previously presented) The composition of Claim 42, wherein the composition is suitable for adoptive administration to a human.

44. (Previously presented) The composition of Claim 42, comprising a T cell clone comprising said first or second isolated T cell population.

45. (Previously presented) The composition of Claim 42, comprising a polyclonal population of T cells comprising said first or second isolated T cell population.

46. (Previously presented) The composition of Claim 42, wherein the first target cell is a neoplastic cell.

47. (Previously presented) The composition of Claim 42, wherein the first antigen is a tumor associated antigen.

Appl. No. : 10/026,066
Filed : December 7, 2001

48. (Previously presented) The composition of Claim 47, wherein the tumor associated antigen is a cancer-testis antigen.

49. (Previously presented) The composition of Claim 47, wherein the tumor associated antigen is selected from the group consisting of NY-ESO, PSMA, SSX-2 and PRAME.

50. (Previously presented) The composition of Claim 47, wherein the tumor associated antigen is a melanoma differentiation antigen.

51. (Previously presented) The composition of Claim 50, wherein the melanoma differentiation antigen is selected from the group consisting of tyrosinase, MelanA, and gp100.

52. (Previously presented) The composition of Claim 42, wherein the first or second MHC is A2.

53. (Previously presented) The composition of Claim 42, wherein the first or second MHC is selected from the group consisting of A1, A3, A24, B7 and B8.

54. (Previously presented) The composition of Claim 42, wherein said first antigen and said second antigen are the same.

55. (Previously presented) The composition of Claim 42, wherein said first target cell and said second target cell are the same.

56. (Previously presented) The composition of Claim 42, comprising from about 10^5 to about 10^8 T cells.

57. (Previously presented) The composition of Claim 42, comprising from about 10^8 to about 10^{11} T cells.